Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 5: Patient Safety and Quality Assurance
5PSQ-017
IMPLEMENTATION AND MONITORING OF A PROTOCOL FOR THE USE OF INTRAVENOUS IRON
5PSQ-016
UNFAVOURABLE OUTCOMES OF BLOOD TRANSFUSIONS IN HOSPITALISED ANAEMIC PATIENTS
5PSQ-015
DRUG INTERACTION BETWEEN NOACs AND ITRACONAZOLE: AN ITALIAN DISTRICT ANALYSIS
5PSQ-014
NOVEL ORAL ANTICOAGULANTS VS VITAMIN K ANTAGONISTS: A COST ANALYSIS
5PSQ-013
PRESCRIPTIONS OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS ADMITTED
5PSQ-012
IMPACT OF THERAPEUTIC PATIENT EDUCATION IN THE PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER
5PSQ-011
VENOUS THROMBOEMBOLIC EVENTS AND TOTAL HIP OR KNEE ARTHROPLASTY: INCIDENCE AND ASSOCIATED FACTORS
5PSQ-010
MANIPULATION OF WARFARIN TABLETS IN PAEDIATRIC CARE: DO WE GIVE THE RIGHT DOSE?
5PSQ-009
CYP2C19 SNP´S INFLUENCE ON CLOPIDOGREL RESPONSE IN CEREBROVASCULAR DISEASE PATIENTS: FINAL RESULTS
5PSQ-008
CYP2C19 SNP´S INFLUENCE ON CLOPIDOGREL RESPONSE IN PERIPHERAL ARTERY DISEASE PATIENTS
5PSQ-007
SEBELIPASE ALFA AS ENZYME REPLACEMENT THERAPY IN THREE PAEDRIATRIC PATIENTS
5PSQ-006
USE OF SUBSTITUTE ENZYMATIC TREATMENT AND SUBSTRATE REDUCTION IN GAUCHER DISEASE
5PSQ-005
SAFETY AND EFFICACY OF FAST-ACTING INSULIN ADDED TO TOTAL PARENTERAL NUTRITION
5PSQ-004
OBSERVATIONAL STUDY OF THE EVOLUTION OF BLOOD GLUCOSE LEVELS AFTER THE CHANGE TO INSULIN DEGLUDEC
5PSQ-003
A QUALITATIVE ANALYSIS OF BARRIERS TO MEDICATION ADHERENCE IN UNCONTROLLED DIABETES – FOCUS ON INSULIN AND SUGGESTIONS FOR PRACTICE IMPROVEMENTS
Pages
« first
‹ previous
…
49
50
51
52
53
54
55
56
57
…
next ›
last »
Follow Us